Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Olivier Sitbon, Marc Humbert, Eric Hachulla, Pierre-Yves Hatron, Gérald Simonneau, Alice Bérezné, Loïc Guillevin, Pierre Clerson, Luc Mouthon, David Launay
Publikováno v:
Chest. 136:1211-1219
Background Pulmonary arterial hypertension (PAH) is a frequent cause of morbidity and mortality in patients with systemic sclerosis (SSc). PAH is generally considered to be a late complication of limited cutaneous SSc. This study identified and inves
Autor:
Mayra Mejía, Carmen Navarro, Andrea Estrada, Moisés Selman, Miguel Gaxiola, Emilio Barrientos, Jorge Rojas-Serrano, Delfino Alonso, Teresa Suarez, Guillermo Carrillo
Publikováno v:
Chest. 136:10-15
Background It has been suggested that the presence of emphysema modifies the outcome of patients with idiopathic pulmonary fibrosis (IPF). In this article we compare clinical features, smoking history, pulmonary function, estimated systolic pulmonary
Publikováno v:
Chest. 131:874-879
Chronic lung diseases like COPD, severe progressive pulmonary hypertension (PH), and interstitial lung diseases all have a lung vascular disease component. Cellular and molecular mechanisms of pulmonary vascular remodeling have been experimentally ex
Autor:
Masanori Kitaichi, Shigeru Tanaka, Michiaki Mishima, Tomohiro Handa, Takateru Izumi, Taishi Nagao, Michio Shigematsu, Kunio Hamada, Sonoko Nagai
Publikováno v:
Chest. 131:650-656
To evaluate the long-term clinical course of patients with idiopathic pulmonary fibrosis (IPF) complicated with pulmonary arterial hypertension.Prospective analysis of consecutive IPF patients undergoing initial workup with right-heart catheterizatio
Publikováno v:
Chest. 131:897-899
Pulmonary hypertension is a common finding in patients with idiopathic pulmonary fibrosis (IPF), and is associated with increased morbidity and mortality. Therapy with sildenafil has been shown to decrease pulmonary vascular resistance in patients wi
Autor:
Marshall S. Riley, Janos Porszasz, Mariëlle P.K.J. Engelen, Karlman Wasserman, Bruce H. Brundage, Joe Miranda
Publikováno v:
Scopus-Elsevier
Nitric oxide (NO), a potent vasodilator, is present in the exhaled air of humans. We wished to quantify NO production in patients with abnormalities of the pulmonary circulation.Nine patients with primary pulmonary hypertension (PPH), six with pulmon
Publikováno v:
Scopus-Elsevier
The purpose of this investigation was to determine the severity of pure restrictive ventilatory impairment that results in right ventricular (RV) dilatation, increased RV wall thickness, and pulmonary hypertension. Two dimensional (2-D) echocardiogra
Autor:
Valerio G. Saglini, Guido Domenighetti
Publikováno v:
Chest. 102:708-714
Study Objective: The present study was undertaken to evaluate at rest the short- and long-term effects of oral nifedipine (N) in patients with pulmonary hypertension (PH). Design and Setting: A prospective study with ten consecutive cases during two
Autor:
Oksana A. Shlobin, Rajeev Saggar, Steven M. Kawut, Steven D. Nathan, Abbas Ardehali, John A. Belperio, Marvin I. Schwarz, Arun S. Karlamangla, David J. Ross, Joseph P. Lynch, David A. Zisman
Publikováno v:
Chest. 133(3)
We have developed a method to screen for pulmonary hypertension (PH) in idiopathic pulmonary fibrosis (IPF) patients, based on a formula to predict mean pulmonary artery pressure (MPAP) from standard lung function measurements. The objective of this
Autor:
Wander de Oliveira Villalba, Percival D. Sampaio-Barros, Elza Maria Figueiras Pedreira de Cerqueira, Ilma Aparecida Paschoal, João Francisco Marques-Neto, Mônica Corso Pereira, Cid A. Leme
Publikováno v:
Chest. 131(1)
Pulmonary involvement is the leading cause of systemic sclerosis (SSc)-related deaths. A simple test to evaluate exercise capacity is the 6-min walk test (6MWT), and the walk distance is used as a primary outcome in clinical trials. Hemoglobin desatu